STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data.

Abstract

AIM:

A prospective investigation of serum thymidine kinase 1 concentration (STK1p) was performed to evaluate its prognostic value in patients with non-small-cell lung carcinoma (NSCLCs).

PATIENTS & METHODS:

The STK1p values of 127 patients were determined by an enhanced chemiluminescent dot blot assay. The patients were recruited from March 2011 to December 2017.

RESULTS:

Kaplan-Meier plot showed that patients with elevated STK1p values had worse overall survival (OS), especially patients of early/middle stages. Multi-variable COX regression showed that STK1p value and combined treatment surgery + chemotherapy were independent prognostic factors for favorable OS.

CONCLUSION:

STK1p is helpful in predicting OS of early/middle stages (I-IIIA) NSCLCs patients following a nonrandomized individual adapted treatment, but is may be not recommended in advanced stages (IIIB + IV) of NSCLCs.

• Authors: Zhenxin Wang, Guoqing Zhang, Zhongcheng Li, Jin Li, Hongbo Ma, Ailian Hei, Shunchang Jiao, Yi Hu, Shengjie Sun, Liangliang Wu, Ji Zhou, Yu Wang, Ellen He, Sven Skog
• Journal: Future science OA (Future Sci OA) Vol. 7 Issue 3 Pg. FSO661 (Nov 23 2020) ISSN: 2056-5623 [Print] England
• PMID: 33552542 (Publication Type: Journal Article)
• Copyright: © 2020 Sven Skog.